The company’s revenue increase 8.1% to ₹`12,958.8 compared to ₹11,982.9 crore in the previous year. A CNBC-TV18 poll had estimated a 9% increase in its revenue at ₹13,039.2 crore.
Net profit came in at ₹2,153.9 crore for Q4FY25, down 19% from ₹2,658.7 crore in the corresponding quarter last year. The Street had estimated a 10% increase in profit at ₹2,934 crore.
The pharma company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) was up 22.4% at ₹3,715.9 crore compared to ₹3,035.15 crore in the fourth quarter of the previous fiscal. The Street had pegged a 19% increase in its EBITDA at ₹3,618 crore.
The company’s margin expanded to 28.7% from 25.3% in the year-ago period. A CNBC-TV18 poll had estimated the margin to be at 27.7% in the fourth quarter.
The company’s board of directors has recommended a final dividend of ₹5.50 per equity share for the financial year 2024–25, subject to shareholder approval at the upcoming annual general meeting.
Dilip Shanghvi, Managing Director, noted that global specialty sales stood at $1.26 billion for FY25, while the US business contributed over 31.4% to consolidated Q4 revenues.
Also Read: Here’s why VRL Logistics shares surged 13% during Thursday’s trading session
The company launched two generic products in the US during the quarter and plans to introduce Leqselvi in the US market in Q2 FY26. While addressing plans to relocate Ilyuma manufacturing to the US, Shanghvi added that the transition could take up to three years.
Looking ahead, the company has guided for mid-to-high single-digit consolidated topline growth in FY26 and expects R&D expenditure to remain between 6–8% of sales. Sun Pharma also announced plans to invest an additional $100 million to develop new specialty products, signalling its continued focus on building a differentiated pipeline.
Shanghvi reiterated that the company remains open to acquisitions, provided they align with its long-term strategy and add shareholder value.
Ahead of the earnings announcement, shares of Sun Pharma closed 0.52% lower at ₹1,722.65 on the BSE.
First Published: May 22, 2025 5:13 PM IST
